Thymic Stromal Lymphopoeitin (TSLP), an alarmin released by airway epithelial cells after stimulation by a variety of irritants, such as airway pollutants, smoke, infections or allergens [99], impacts both T2 and non-T2 pathways; thus, an inhibition of this molecule may present a novel therapeutic target for T2-low asthma [100]. The gene discussed is TSLP; the disease is asthma.